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1 The eect on cholinergic analgesia of inactivation of the M1 gene by an antisense
oligodeoxyribonucleotide (aODN) was investigated in the mouse hot plate test. Mice received a
single intracerebroventricular (i.c.v.) injection of anti-M1 aODN (0.3, 1.0 or 2.0 nmol per injection),
degenerate ODN (dODN) or vehicle on days 1, 4 and 7.
2 A dose-dependent inhibition of the antinociception induced by the muscarinic agonists
oxotremorine (0.1 mg kg71 s.c.) and McN-A-343 (30 mg per mouse i.c.v.) and the cholinesterase
inhibitor physostigmine (0.2 mg kg71 s.c.) was observed 24 h after the last i.c.v. injection of aODN.
Time-course experiments revealed that, after the end of the aODN treatment, sensitivity to analgesic
drugs progressively appeared reaching the normal range at 96 h.
3 The anti-M1 aODN was selective against muscarinic antinociception since the enhancement of
pain threshold produced by morphine and baclofen were not aected by the above-mentioned
treatment. dODN, used as control, did not aect muscarinic antinociception.
4 Binding studies evidenced a selective reduction of M1 receptor levels in the hippocampus of
aODN-treated mice.
5 Neither aODN, dODN nor vehicle produced any behavioural impairment of mice as revealed by
the rota-rod and Animex experiments.
6 These results indicate that activation of M1 muscarinic receptor subtype is fundamental to induce
central cholinergic analgesia in mice.
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Introduction
It is widely accepted that organisms possess endogenous
system within the central nervous system that inhibit
nociceptive transmission. Several reports have provided
evidence for the critical involvement of the cholinergic system
in such pain inhibitory pathways. The first observation that the
cholinesterase inhibitor physostigmine increased the pain
threshold in man was made more than 60 years ago (Pellandra,
1933). Since then, a vast literature has appeared describing the
antinociceptive action of both cholinesterase inhibitors and
cholinomimetic drugs (Hartvig et al., 1989).
The five types of mammalian muscarinic receptors, m1
through m5, dier in primary structure as determined by
molecular cloning (Caufield, 1993). The molecularly defined
m1, m2 and M3 receptors correlate with the pharmacologically
defined binding M1, M2 and M3 sites in mammalian tissues
(Caufield, 1993). Antinociception induced by muscarinic drugs
has been reported to be antagonized by pretreatment with
either M1, M2 or M3 muscarinic receptor subtype antagonists,
even if a major role seems to be played by M1 receptors (Yaksh
et al., 1985; Gillbert et al., 1989; Smith et al., 1989; Zhuo &
Gebhart, 1991; Bartolini et al., 1992; Ghelardini et al., 1996;
Naguib & Yaksh, 1997). It has also been suggested the
involvement of activation of a2-adrenoceptors, 5-HT1C/2 and 5-
HT3 serotoninergic receptor subtypes (Pavone & Fagioli, 1992;
Iwamoto & Marion, 1993), but these results are controversial
(Naguib & Yaksh, 1994).
Since the available pharmacological muscarinic receptor
antagonists are not completely selective among the muscarinic
receptor subtypes (Caufield, 1993), the aim of the present study
was to investigate further the role of M1 receptors in the
modulation of the pain threshold by using a more selective
experimental tool. To this purpose, an antisense oligodeoxyr-
ibonucleotide (aODN) able to inactivate M1 gene expression
was used. An aODN is a short segment of synthetic DNA
having a sequence complementary to a portion of targeted
mRNAs which prevents translation and/or mediates mRNA
cleavage by the enzyme RNase H. aODNs specifically bind to
targeted mRNAs H and, therefore, down-regulate the
synthesis of the encoded protein representing useful pharma-
cological tools for exploring neurobiological processes at the
molecular level (Wahlestedt, 1994; Crooke & Bennett, 1996;
Galeotti et al., 1997; Ghelardini et al., 1997; Meiri et al., 1997).
aODN can transiently inactivate a single gene and, therefore,
can inactivate receptor functions in a more specific and
selective manner than receptor antagonists. The eects on
antinociceptive processes of anti-M1 aODN were evaluated in
mice by means of the hot-plate test, and a degenerate ODN (an
oligonucleotide accounting for the eventual aODN aspecific
eects) was used as control.
Methods
Animals
Male Swiss albino mice (24 – 26 g) from Morini (San Polo
d’Enza, Italy) were used. Fifteen mice were housed per cage.
The cages were placed in the experimental room 24 h before
the test for acclimatization. The animals were fed a standard
laboratory diet and tap water ad libitum and kept at 23+18C
with a 12 h light/dark cycle, light at 07.00 h.
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Antisense oligonucleotides
Low cell permeability and the high degradation of natural
phosphodiester oligomers are considerable drawbacks in the
application of aODNs both in vitro and in vivo. To
overcome these drawbacks, phosphorothioate-capped phos-
phorodiester oligonucleotides were used. The above-men-
tioned compounds are a class of ODN derivatives shown to
maintain more stable and eective concentrations in the
brain when compared with their unmodified counterpart
(Whitesell et al., 1993). Phosphodiester oligonucleotides
(ODNs) protected by terminal phosphorothioate double
substitution (capped ODNs) against possible exonuclease-
mediated degradation were purchased from Genosys (Cam-
bridge, England) and purified by high-performance liquid
chromatography (HPLC). The 18-mer antisense ODN
(aODN) 5’-CAC TGA GGT GTT CAT TGC-3’ (phosphor-
othioate residues are underlined) complementary to the
residues 112-129 of the published mouse M1 cDNA sequence
(Shapiro et al., 1988) and the 18-mer fully degenerated ODN
(dODN) 5’-NNN NNN NNN NNN NNN NNN-3’ (where
N is G, or C, or A, or T and phosphorothioate residues are
underlined) were vehiculated intracellularly by an artificial
cationic lipid (DOTAP, Boehringer-Mannheim, Germany) to
enhance both uptake and stability, as described previously
(Capaccioli et al., 1993; Quattrone et al., 1994). aODN or
dODN (100 – 400 mM) were preincubated at 378C for 30 min
with 13 mM DOTAP, sterilized through a 0.2 mm filter and
supplied to mice by i.c.v. injection of a 5 ml solution as
described in the next section.
GenBank accession numbers
The accession number of the cDNA sequence for the mouse
muscarinic receptor subtype reported in this paper (M1) is
J04192.
I.c.v. injection of oligonucleotides
Mice were randomly assigned to anti-M1 aODN, dODN,
vehicle, saline or naive group. The antisense and dODNs were
dissolved in a vehicle constituted by DOTAP. Each group
received a single i.c.v. injection on days 1, 4 and 7 whereas naive
animals did not receive any treatment. I.c.v. administration was
performed under ether anaesthesia with isotonic saline as
solvent, according to the method described by Haley &
McCormick (1957). During anaesthesia, mice were grasped
firmly by the loose skin behind the head. A hypodermic needle
(0.4 mm external diameter) attached to a 10 ml syringe was
inserted perpendicularly through the skull and no more than
2 mm into the brain of the mouse, where 5 ml ODNs were then
administered. The injection site was 1 mm to the right or left
from the midpoint on a line drawn through to the anterior base
of the ears. Injectionswere performed randomly into the right or
left ventricle. To ascertain thatODNswere administered exactly
into the cerebral ventricle, some mice were injected with 5 ml of
diluted 1 : 10 India ink and their brains were examined
macroscopically after sectioning. The accuracy of the injection
technique was evaluated with 95% of injections being correct.
Hot-plate test
The method adopted was described by O’Callaghan &
Holtzman (1975). Mice were placed inside a stainless steel
container, which was set thermostatically at 52.5+0.18C in a
precision water-bath from KW Mechanical Workshop, Siena,
Italy. Reaction times (s), were measured with a stopwatch
before and 15, 30 and 45 min after administration of the
analgesic drugs. The endpoint used was the licking of the fore
or hind paws. Those mice scoring less than 12 and more than
18 s in the pretest were rejected (30%). An arbitrary cut-o
time of 45 s was adopted.
Rota-rod test
The test was performed according to the method described by
Kuribara et al. (1977). Briefly, the apparatus consisted of a
base platform and a rotating rod of 3 cm diameter with a non-
slippery surface. The rod was placed at a height of 15 cm from
the base. The rod, 30 cm in length, was divided into five equal
sections by six disks. Thus, up to five mice were tested
simultaneously on the apparatus, with a rod-rotating speed of
16 r.p.m. The integrity of motor coordination was assessed on
the basis of endurance time of the animals on the rotating rod.
One day before the test, the animals were trained twice. On the
day of the test only the mice that were able to stay balanced on
the rotating rod between 90 and 120 s (cut-o time) were
selected for testing. The performance time was measured
before and 15, 30 and 45 min after treatment.
Spontaneous activity meter (Animex)
Locomotor activity in mice was quantified using an Animex
activity meter Type S (LKB, Farad, Sweden) set to maximum
sensitivity. Every movement of mice, which were placed on the
top of the Animex activity meter, produced a signal due to
variation in inductance and capacity of the apparatus
resonance circuit. Then signals were automatically converted
to numbers. On the day of the experiment the mice were
treated and then the cage, containing five mice, was put on the
measuring platform. Activity counts were made for 10 min
starting 30 min after the beginning of the test. Because of the
arbitrary scale adopted to quantify movements, drug-treated
mice were always compared with saline-treated ones.
Binding assay – membrane preparation
Male mice used for the [3H]-telenzepine binding assays were
killed by decapitation 24 h after the last i.c.v. injection of
aODN, dODN or vehicle. The brain was removed, rinsed with
ice-cold 0.9% saline solution and dissected into two regions:
cortex and hippocampus. Tissues were homogenized in 40 vol
HEPES buer containing (mM): HEPES 20, NaCl 100, MgCl2
10 and phenyl-methyl-sulphonil-fluoride (PMSF) 0.01, pH 7.4
for 15 s using an Ultraturrax homogenizer at half of the
maximum speed. Homogenates were centrifugated at 10006g
for 5 min; supernatants were again centrifuged at 48,0006g
for 30 min and the resultant sediments were immediately
frozen at 7808C until binding experiments were performed.
Ligand binding assay
Frozen pellets were dispersed in HEPES buer and then spun
at 48,0006g for 30 min. The resulting pellets were rehomo-
genized in the above-mentioned buer and used for the
binding assays; an aliquot was taken for protein determina-
tions. Aliquots of membranes (0.4 – 0.6 mg ml71) were
incubated in a final volume of 0.5 ml ligands in HEPES buer
at 378C for 2 h; [3H]-telenzepine was present at 0.4 nM in tubes
containing increasing concentrations (0.3 – 10,000 nM) of
unlabelled telenzepine and at 0.05 – 0.4 nM in tubes without
unlabelled ligand. All measurements were obtained in
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duplicate. After incubation, bound radioactivity was separated
by filtration through Whatman GF/C filters presoaked in
0.1% polyethyleneimine (PEI) using the Brandel M-48R cell
harvester (Gaithersburg, MD, U.S.A.). Filters were washed
twice with 5 ml of 50 mM Tris-HCl buer, pH 7.4 containing
10 mMMgCl2 and counted in 5 ml of FilterCount (Packard) in
a liquid scintillation counter TRI-CARB 1900TR (Packard).
Protein content was measured using the Pierce protein assay
reagent (Pierce Chemical Co., Rockford, IL, U.S.A.),
according to the standard assay procedure recommended by
the manufacturer and based on the method of Bradford (1976)
using bovine serum albumin as a standard.
Drugs
The following drugs were used: baclofen (b-p-chlorophenyl
GABA), physostigmine hemisulphate (Sigma, Italy); morphine
hydrochloride (U.S.L. 10/D, Firenze); McN-A-343 (4-(N-[3-
chlorophenyl]-carbamoyloxy)-2-butynyl-trimethylammonium
chloride), oxotremorine methiodide (R.B.I.); [3H]-telenzepine
(DuPont NEN, Italy). Other chemicals were of the highest
quality commercially available. Drugs were dissolved in
isotonic (NaCl 0.9%) saline solution immediately before use.
Drug concentrations were prepared so that the necessary dose
could be administered in a volume of 5 ml per mouse by
intracerebroventricular (i.c.v.) injection and 10 ml kg71 by
subcutaneous (s.c.) injection.
Data analysis
All experimental results are given as the mean+s.e.mean.
An analysis of variance ANOVA, followed by Fisher’s
Protected Least Significant Dierence procedure for post
hoc comparison, were used to verify significance between
two means of behavioural results. Data were analysed with
the StatView software for the Macintosh (1992). The
binding data were evaluated quantitatively using the
Ligand (Munson & Rodbard, 1980) computer program;
this type of analysis provides optimal estimates of binding
parameters (anity constants, binding capacities, non
specific binding). P values of less than 0.05 were
considered significant.
Results
Eect of aODN on muscarinic antinociception
Mice were pretreated with a single i.c.v. injection of antisense
ODN (aODN) to M1 gene, degenerate ODN (dODN) or
vehicle on days 1, 4 and 7. The eect of aODN pretreatment
on oxotremorine (0.1 mg kg71 s.c.), physostigmine
(0.2 mg kg71 s.c.) and McN-A-343 (30 mg per mouse i.c.v.)
induced antinociception was then evaluated in the mouse hot-
plate test.
aODN, at the dose of 0.3 nmol per i.c.v. injection, did
not significantly aect oxotremorine (Figure 1A), physos-
tigmine (Figure 2A) and McN-A-343 (Figure 3A) analgesia.
At the dose of 1.0 and 2.0 nmol per i.c.v. injection, aODN
dose-dependently prevented oxotremorine (Figure 1B,C),
physostigmine (Figure 2B,C) and McN-A-343 (Figure
3B,C) antinociception. This antagonistic eect was detected
24 h after the last i.c.v. injection.
The regression lines which show the dose-dependent
reduction of oxotremorine, physostigmine and McN-A-343
antinociception produced by increasing concentrations of
aODN are shown in Figure 4A–C respectively. The percentage
of the maximum analgesic eect was evaluated in correspon-
dence with the maximum eect of analgesic compounds that
occurred 15 min after McN-A-343 and 30 min after oxotre-
morine and physostigmine administration. The hot-plate test
was performed 24 h after the end of the ODNs treatments.
A time-course study for aODN antagonistic eect showed
that 48 h after the last i.c.v. injection of ODNs the
antinociception produced by oxotremorine, physostigmine
and McN-A-343 was completely prevented (Figure 5). At
72 h the aODN eect was still detectable against physos-
tigmine and McN-A-343 antinociception (Figure 5B,C), but
not against oxotremorine antinociception (Figure 5A). At
96 h, the three analgesic compounds were able to enhance
the pain threshold at the same intensity in aODN-, dODN-
and vehicle-treated mice indicating the loss of antagonistic
activity by the anti-M1 aODN (Figure 5).
The aODN pretreatment (2.0 nmol per i.c.v. injection) did
not prevent the analgesia induced by morphine (8 mg kg71
i.p.; Figure 6A) and baclofen (4 mg kg71 s.c., Figure 6B) 24 h
after the end of ODNs administration.
Figure 1 Prevention of oxotremorine (0.1 mg kg71 s.c)-induced
antinociception by pre-treatment with an antisense ODN (aODN)
to M1 gene in the mouse hot-plate test. Mice were i.c.v. injected with
vehicle, aODN or degenerated ODN(dODN) at the dose of 0.3 (A),
1.0 (B) and 2.0 nmol (C) per single i.c.v. injection on days 1, 4 and 7.
The hot plate test was performed 24 h after the last i.c.v. injection.
Vertical lines give s.e.mean. Each point represents the mean of 12 – 18
mice. *P50.05; **P50.01 in comparison with dODN+oxotremor-
ine-treated mice.
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The aODN pretreatment (2.0 nmol per i.c.v. injection) did
not reduce the pain threshold in mice showing a lack of any
hyperalgesic eect (Figures 1 – 5).
The pretreatment with the dODN never modified oxo-
tremorine-, physostigmine and McN-A-343-induced antinoci-
ception in comparison with mice injected with vehicle as shown
in Figures 1 – 4.
The i.c.v. injection of a solution of DOTAP, used as vehicle,
did not modify the licking latency of mice in comparison with
naive and saline-treated animals (Table 1). Furthermore,
DOTAP did not influence the sensitivity of mice to the
analgesic treatments (Table 1).
Determination of M1 receptor protein brain levels
Saturation analysis demonstrates that [3H]-telenzepine binds
with high anity and saturable manner to a homogeneous
class of sites in membranes from brain, hippocampus and
cortex of dODN- and aODN-treated mice. A decrease in [3H]-
telenzepine binding was observed in both cortex and
hippocampus even if statistical significance was reached only
in the hippocampus. [3H]-telenzepine binding in the whole
brain was not appreciably aected by the treatment and, in any
case, KD values remained unaected (data not shown).
Eect of aODN on mouse behaviour
Mice pretreated with aODN (2.0 nmol per injection) or
dODN (2.0 nmol per injection) were evaluated for motor
coordination and spontaneous motility respectively by use of
the rota-rod test (Table 2) and Animex Apparatus. Both
tests were performed 24 h after the last i.c.v. injection.
The endurance time, evaluated before and 15, 30 and
45 min after the beginning of the rota-rod test, showed the lack
of any impairment in the motor coordination of animals
pretreated with aODN and dODN in comparison with saline-
and vehicle-treated mice (Table 2).
The spontaneous motility of mice, expressed as counts in
10 min, was unmodified by pretreatment with aODN
2.0 nmol per injection (604+47) or dODN 2.0 nmol per
Figure 3 Prevention of McN-A-343 (0.03 mg per mouse i.c.v.)-
induced antinociception by pretreatment with an antisense ODN
(aODN) to M1 gene in the mouse hot-plate test. Mice were i.c.v.
injected with vehicle, aODN or degenerated ODN (dODN) at the
dose of 0.3 (A), 1.0 (B) and 2.0 nmol (C) per single i.c.v. injection on
days 1, 4 and 7. The hot plate test was performed 24 h after the last
i.c.v. injection. Vertical lines give s.e.mean. Each point represents the
mean of 12 – 15 mice. *P50.05; **P50.01 in comparison with
dODN+McN-A343-treated mice.
Figure 2 Prevention of physostigmine (0.2 mg kg71 s.c)-induced
antinociception by pre-treatment with an antisense ODN(aODN) to
M1 gene in the mouse hot-plate test. Mice were i.c.v. injected with
vehicle, aODN or degenerated ODN (dODN) at the dose of 0.3 (A),
1.0 (B) and 2.0 nmol (C) per single i.c.v. injection on days 1, 4 and 7.
The hot plate test was performed 24 h after the last i.c.v. injection.
Vertical lines give s.e.mean. Each point represents the mean of 10 – 14
mice. *P50.05; **P50.01 in comparison with dODN+physostig-
mine-treated mice.
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injection (518+89) as revealed by the Animex Apparatus in
comparison with saline- (622+83) and vector-treated
(561+54) mice.
Discussion
Our results clearly demonstrate that M1 muscarinic receptor
subtype plays an essential role in the modulation of pain
perception. Cholinergic antinociception induced both di-
rectly, through muscarinic agonists, and indirectly, by
enhancing ACh extracellular levels through cholinesterase
inhibitors, is prevented, in a dose-related manner, by i.c.v.
administration of an antisense to the M1 gene coding for the
mouse M1 receptor.
The present data indicate that cholinergic antinociception in
mice is mediated by M1 receptor stimulation confirming and
extending previous results which, by using pharmacological
agonists and antagonists, evidenced the involvement of M1
receptors in muscarinic analgesia (Bartolini et al., 1992;
Iwamoto & Marion, 1993; Ghelardini et al., 1996; Naguib &
Yaksh, 1997). Furthermore, the employment of an aODN to
the M1 receptor allows clear elucidation of the role of the M1
receptor in pain perception without any potential interference
due to interaction with the other muscarinic receptor subtypes.
The above-mentioned literature data were obtained by using
pharmacological M1 receptor antagonists which, even if they
are the most selective M1/M2-M3 compounds available, are
endowed with a quite weak selectivity for M1 receptors. The
selectivity ratio values are three for dicyclomine (Giachetti et
Figure 5 Eect of antisense ODN (aODN) to M1 gene on
oxotremrine (0.1 mg kg71 s.c.; A), physostigmine (0.2 mg kg71 s.c.;
B) and McN-A-343 (0.3 mg per mouse i.c.v.; C)-induced antinocicep-
tion 48, 72 and 96 h after the end of the aODN treatment. Mice were
i.c.v. injected with vehicle, a aODN or degenerated ODN (dODN) at
the dose of 2.0 nmol per single i.c.v. injection on days 1, 4 and 7.
Modification of pain threshold was evaluated by using the mouse
hot-plate test. The licking latency was detected 15 min after McN-A-
343 and 30 min after oxotremorine and physostigmine administra-
tion. Vertical lines give s.e.mean. Each column represents the mean of
10 – 14 mice. 6P50.05; *P50.01 in comparison with vehicle-
oxotremorine/physostigmine/MCN-A-343-treated mice.
Figure 4 Eect of increasing concentrations of aODN to M1 gene
on oxotremorine (0.1 mg kg71 s.c.; A), physostigmine (0.2 mg kg71
s.c.; B) and McN-A-343 (0.3 mg per mouse i.c.v.; C)-induced
antinociception in the mouse hot-plate test. Mice received a single
i.c.v. injected of aODN (0.3, 1.0 or 2.0 nmol per injection) on days 1,
4 and 7. The hot plate test was performed 24 h after the last i.c.v.
injection. The evaluation of the analgesic eect was carried out
15 min after McN-A-343 and 30 min after oxotremorine and
physostigmine administration. Each point represents the mean of at
least 15 mice.
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al., 1986), 29 for pirenzepine and 176 for S-(7)-ET 126
(Ghelardini et al., 1996). These values do not exclude that, at
doses active on antinociceptive processes, these compounds
can also interact with other muscarinic receptor subtypes such
as M2 and M3, that has been reported to be involved in
modulation of pain perception (Iwamoto & Marion, 1993;
Naguib & Yaksh, 1997).
The aODN treatment induces a transient prevention of
muscarinic antinociception since the inhibition of oxotremor-
ine, McN-A-343 and physostigmine antinociception disap-
peared 96 h after the last i.c.v. injection of the aODN. This
return to normal sensitivity to analgesic treatments implies
both the total reversal of aODN-induced specific inhibition of
M1 gene expression and a lack of damage or toxicity associated
with aODN treatment.
In these experimental conditions, anti-M1 aODN did not
modified the licking latency values of mice in comparison with
control groups excluding that the prevention of oxotremorine,
McN-A-343 and physostigmine antinociception is due to
hyperalgesic eect of the treatment used. Furthermore, the
antinociception induced by activation of other neurotransmit-
ter systems able to enhance the pain threshold, such as opioid
and GABAergic, were not modified by anti-M1 aODN
treatment. These data indicate not only the specificity of the
aODN treatment, but also lead us to exclude a correlation
between these two antinociceptive systems and muscarinic
analgesia.
In comparison with naive and saline groups, dODN and
vehicle treatments did not modify the enhancement of pain
threshold produced by both muscarinic agonists and
cholinesterase inhibitors, ruling out the possibility that the
antagonism exerted by aODN could be caused by sequence-
independent eects on cerebral structures. This claim is
supported by results obtained from the quantitative RT –PCR
analysis of ODN eects on M1 gene expression. Quantitative
results of M1 mRNA brain levels following aODN treatment
confirmed that phenotypic eects of anti-M1 aODN on pain
modulation were actually due to the specific inhibition of M1
gene expression since dODN did not modify M1 mRNA brain
levels (Ghelardini et al., 1999).
Through molecular cloning, five muscarinic receptor
subtypes have been identified and renamed m1-m5 based on
their order of discovery (Bonner, 1989). Muscarinic receptors
can be generally grouped on the basis of the signal
Table 1 Comparison between vehicle (DOTAP) and saline pretreatment on oxotremorine, physostigmine and McN-A-343-induced
antinociception in the mouse hot-plate test
Licking latency (s)
Pretreatment Before After treatment
(5 ml i.c.v.) Treatment Dose treatment 15 min 30 min 45 min
Saline
Vehicle
–
Saline
Vehicle
–
Saline
Vehicle
–
Saline
Vehicle
–
Saline
Saline
Saline
Oxotremorine
Oxotremorine
Oxotremorine
Physostigmine
Physostigmine
Physostigmine
McN-A-343
McN-A-343
McN-A-343
0.1 mg kg71 s.c.
0.1 mg kg71 s.c.
0.1 mg kg71 s.c.
0.2 mg kg71 s.c.
0.2 mg kg71 s.c.
0.2 mg kg71 s.c.
0.3 mg kg i.c.v.
0.3 mg kg i.c.v.
0.3 mg kg i.c.v.
14.6+1.3
14.8+1.4
13.9+0.9
13.7+1.1
15.1+0.9
14.4+1.2
14.2+1.0
15.2+1.4
15.5+0.8
12.6+1.4
15.3+1.1
14.7+1.3
14.1+1.2
15.0+1.0
13.7+0.9
22.4+2.2*
20.5+1.8^
19.2+1.6^
20.1+1.6^
21.5+2.8^
18.9+1.6
25.8+2.0*
27.6+2.1*
28.1+2.3*
15.2+1.5
14.7+1.2
14.3+0.8
27.3+1.7*
26.6+2.1*
24.9+2.3*
31.2+1.7*
29.4+2.1*
28.7+2.5*
22.1+1.2*
20.3+1.9^
19.6+2.1^
15.0+1.6
13.6+1.6
14.9+1.1
17.7+2.6
18.9+2.1
18.5+1.7
23.4+1.6*
22.5+1.7*
21.6+1.7^
16.6+1.5
17.5+1.2
15.8+1.9
Mice were i.c.v. injected with saline or vehicle on days 1, 4 and 7. Non-pretreated (naive) mice did not receive any i.c.v. injection. The
experiment was performed 24 h after the last i.c.v. injection. Each value represents the mean of 10 – 18 mice with the exception of
vector-saline which were 29. ^P<0.05; *P<0.01 versus the corresponding control mice.
Figure 6 Lack of prevention of morphine (8 mg kg71 s.c.; A) and
baclofen (4 mg kg71 s.c.; B)-induced antinociception by pretreatment
with an antisense ODN (aODN) to M1 gene in the mouse hot-plate
test. Mice were i.c.v. injected with vehicle, aODN or degenerated
ODN (dODN) at the dose of 2.0 nmol per single i.c.v. injection on
days 1, 4 and 7. The hot plate test was performed 24 h after the last
i.c.v. injection. Vertical lines give s.e.mean. Each point represents the
mean of 12 – 15 mice.
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transduction mechanism used in two main groups: those
which mobilize intracellular calcium (m1, m3 and m5) and
those which inhibit adenylate cyclase (m2 and m4) (Felder,
1995). Considering the similarity among the structures of the
muscarinic receptors, a specific anti-M1 aODN was employed
in order to inhibit selectively the expression of this receptor
subtype without interfering with the other subtypes. The
sequence encompassing the translation start sites of mRNAs,
which is considered particularly prone to aODN action
(Goodchild, 1989; Stein & Cheng, 1993), was compared
among the murine known muscarinic receptors gene family,
to design a specific antimouse M1 aODN with a very low
sequence homology even with the nearest other members of
the muscarinic receptor family. An homology search in the
Genbank database confirmed the absolute specificity of the
employed aODN. Furthermore, considering the described
sequence-independent, non-antisense eects of ODNs (Storey
et al., 1991; Gao et al., 1992; Blagosklonny & Neckers, 1994;
Schick et al., 1995), a fully degenerated phosphorothioate
capped phosphodiester ODN (dODN) was used as the most
suitable control for these potentially confusing eects. The
dODN used is a collection of about 361014 dierent
molecular species. At concentrations achieved in the
nanomolar to micromolar range in in vitro antisense
experiments, every species, i.e. every ODN of defined
sequence, was present at the site of action at a concentration
less than 10718 M, which is totally insucient to achieve any
antisense, or generally sequence-dependent, cellular eect.
Therefore, if ODN i.c.v. administration per se had achieved
any biological response, this would have been present in
ODN-treated controls.
aODN treatment produced a reduction at both M1 mRNA
and protein levels. By performing binding experiments in
hippocampus and cortex of anti-M1 treated mice, we
documented a reduction in the binding sites of [3H]-
telenzepine to M1 receptors in both cerebral structures. We
investigated the eects produced by aODN treatment in M1
receptor levels in these two areas since M1 receptors are
expressed at the highest levels in particular brain areas, such
as the cortex and hippocampus (Cortes & Palacios, 1986;
Cortes et al., 1986). Present binding results are in agreement
with previous experiments performed in the rat in which a
reduction of [3H]-QNB binding in the cortex and hippocam-
pus was observed after treatment with an aODN to the m1
muscarinic receptor mRNA (Zang et al., 1994). Fewer M1
receptors in the hippocampus of anti-M1 aODN-treated mice
confirms the importance of a complete integrity and
functionality of M1 receptors in the modulation of pain
perception.
The anti-M1 aODN does not cause any detectable
modification in mouse gross behaviour. At active doses,
aODN to M1 receptor did not impair motor coordination nor
modify spontaneous motility in comparison with dODN- and
vehicle-treated groups. Since animals were trained to balance
on the rotating rod before performing the rota rod test, the
lack of variation of the endurance time represents an index of
the absence of motor incoordination. By contrast, a reduction
of the endurance time after treatment indicates impaired
mouse motor coordination that could lead to a misinterpreta-
tion of the results obtained in the hot-plate test. Mice, even if
still sensitive to the thermal stimulus used in the hot plate test,
may have no reaction to pain (licking of paws) because of their
impaired motility.
Seen as a whole, our data indicate that activation of M1
muscarinic receptor subtype plays a fundamental role in the
mechanism responsible for the induction of cholinergic
analgesia in mice.
This work was supported by MURST. The authors wish to thank
Mary Forrest for linguistic revision of the manuscript.
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